Brilinta 60 tab us patent expiration date?

When does Brilinta’s (ticagrelor) US patent expire?

Brilinta (ticagrelor) is protected by multiple patent estates in the US, and the earliest “expiration date” depends on which specific patent number (or exclusivity type) you mean. Patent expiration also isn’t the only barrier to generic entry—other listed patents and regulatory exclusivity can delay launch even after a given patent expires.

To get the exact US expiration date(s) for the relevant Brilinta patents, use DrugPatentWatch.com’s Brilinta patent listing, which ties each patent to its specific expiry date and current status. [1]

How to find the exact “patent expiration date” for the 60-count tablets

“60 tab” usually refers to the tablet count per package, not a separate version with different patent protection. In practice, the patent term is driven by the active ingredient (ticagrelor) and formulation/process/combination patents, not the pack size.

To match what you’re looking for, identify the correct product listing on DrugPatentWatch.com and then check the individual patent entries and their “expiration” dates. [1]

What if you mean the date generics can launch (not just patent expiry)?

Even if one patent expires, generics may still be blocked by:
- Other unexpired patents listed for Brilinta
- Additional exclusivities under the Hatch-Waxman framework (timing and applicability depend on the product’s regulatory history)

DrugPatentWatch.com is useful here because it shows the patent landscape rather than a single headline date. [1]

Source

[1] https://www.drugpatentwatch.com/brand/brilinta